Pre-made Vanucizumab benchmark antibody ( Bispecific mAb, anti-ANGPT2;VEGFA therapeutic antibody, Anti-AGPT2/ANG2/LMPHM10;VPF/VEGF/MVCD1 Antibody) for drug discovery and mechanism of action (MOA) research

Pre-Made Vanucizumab biosimilar, Bispecific mAb, Anti-ANGPT2;VEGFA Antibody: Anti-AGPT2/ANG2/LMPHM10;VPF/VEGF/MVCD1 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Vanucizumab (INN; development code RG7221) is an experimental humanized monoclonal antibody designed for the treatment of cancer.

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	Price(In USD)	Qty (Quantity)	Sum(In USD)
GMP-Bios-ab-612-1mg	1mg	Inquiry
GMP-Bios-ab-612-10mg	10mg	Inquiry
GMP-Bios-ab-612-100mg	100mg	Inquiry
GMP-Bios-ab-612-xmg	＞100mg	Inquiry
			Shipping Cost:	760.00
			Total:

Description

Products Name (INN Index)	Pre-Made Vanucizumab biosimilar, Bispecific mAb, Anti-ANGPT2;VEGFA Antibody: Anti-AGPT2/ANG2/LMPHM10;VPF/VEGF/MVCD1 therapeutic antibody
INN Name	Vanucizumab
Target	ANGPT2;VEGFA
Format	Bispecific mAb
Derivation	Bispecific antibody
Species Reactivity	Human
CH1 Isotype	IgG1
VD LC	Lambda;Kappa
Highest_Clin_Trial (Jan '20)	Phase-II
Est. Status	Discontinued
100% SI Structure	4imk:AD:BC/4iml:HL:AB;1bj1:HL:KJ
99% SI Structure	None;None
95-98% SI Structure	None;6bft:AB:HL/1cz8:HL:YX
Year Proposed	2014
Year Recommended	2015
Companies	Roche
Conditions Approved	na
Conditions Active	na
Conditions Discontinued	Solid tumours;Colorectal cancer
Development Tech	na